{
    "id": "18fa8a54-6196-4635-a213-f78a9236f3d6",
    "indications": "buprenorphine sublingual tablets indicated treatment opioid dependence preferred induction . buprenorphine sublingual tablets used part complete treatment plan include counseling psychosocial support .",
    "contraindications": "administer buprenorphine sublingual tablets sublingually single daily dose . ( 2.1 ) strongly consider prescribing naloxone time buprenorphine sublingual tablets initiated renewed patients treated opioid disorder potential relapse , putting risk opioid overdose ( 2.2 ) avoid precipitating withdrawal , induction buprenorphine sublingual tablets undertaken objective clear signs withdrawal evident . ( 2.3 ) . buprenorphine naloxone sublingual film buprenorphine naloxone sublingual tablet generally initiated two days buprenorphine sublingual tablets titration . ( 2.4 ) administer buprenorphine sublingual tablets directed full prescribing information . ( 2.3 , 2.4 , 2.5 ) buprenorphine sublingual tablets must administered whole . cut , chew , swallow buprenorphine sublingual tablets . ( 2.5 ) discontinuing treatment , gradually taper avoid signs symptoms withdrawal . ( 2.9 )",
    "warningsAndPrecautions": "product : 50090-7559 ndc : 50090-7559-0 30 tablet bottle",
    "adverseReactions": "buprenorphine sublingual tablets contraindicated patients history hypersensitivity buprenorphine , serious , including anaphylactic shock , reported [ ( 5.9 ) ] .",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "BUPRENORPHINE HYDROCHLORIDE",
            "code": "56W8MW3EN1"
        }
    ],
    "organization": "A-S Medication Solutions",
    "name": "buprenorphine hydrochloride",
    "effectiveTime": "20250528",
    "indications_original": "Buprenorphine sublingual tablets is indicated for the treatment of opioid dependence and is preferred for induction. Buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.",
    "contraindications_original": "Administer buprenorphine sublingual tablets sublingually as a single daily dose. ( 2.1 ) Strongly consider prescribing naloxone at the time buprenorphine sublingual tablets is initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose ( 2.2 ) To avoid precipitating withdrawal, induction with buprenorphine sublingual tablets should be undertaken when objective and clear signs of withdrawal are evident. ( 2.3 ). Buprenorphine and naloxone sublingual film or buprenorphine and naloxone sublingual tablet is generally initiated after two days of buprenorphine sublingual tablets titration. ( 2.4 ) Administer buprenorphine sublingual tablets as directed in the Full Prescribing Information. ( 2.3 , 2.4 , 2.5 ) Buprenorphine sublingual tablets must be administered whole. Do not cut, chew, or swallow buprenorphine sublingual tablets. ( 2.5 ) When discontinuing treatment, gradually taper to avoid signs and symptoms of withdrawal. ( 2.9 )",
    "warningsAndPrecautions_original": "Product:    50090-7559\n                  NDC:    50090-7559-0   30 TABLET in a BOTTLE",
    "adverseReactions_original": "Buprenorphine sublingual tablets is contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported\n \n  [see Warnings and Precautions (\n  \n   5.9)]\n \n  ."
}